Phathom Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
PHAT$5.45+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Deficit
(in thousands, except share amounts)
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Deficit | |
| Balance at December 31, 2024 | 68,518,238 | $6 | 19 | $1,009,425 | $(1,263,011) | $(253,580) |
| 401(k) matching contribution | 290,165 | — | — | 2,127 | — | 2,127 |
| Vesting of restricted stock units | 508,568 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 5,540 | — | 5,540 |
| ESPP shares issued | 321,099 | — | — | 1,853 | — | 1,853 |
| Net loss | — | — | — | — | (94,316) | (94,316) |
| Balance at March 31, 2025 | 69,638,070 | 6 | 19 | 1,018,945 | (1,357,327) | (338,376) |
| Vesting of restricted stock units | 456,677 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 8,272 | — | 8,272 |
| Issuance of common stock from exercises of stock options | 9,672 | — | — | 80 | — | 80 |
| Net loss | — | — | — | — | (75,810) | (75,810) |
| Balance at June 30, 2025 | 70,104,419 | $6 | 19 | $1,027,297 | $(1,433,137) | $(405,834) |
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Deficit | |
| Balance at December 31, 2023 | 57,970,044 | $5 | 19 | $855,921 | $(928,685) | $(72,759) |
| 401(k) matching contribution | 93,736 | — | — | 712 | — | 712 |
| Vesting of restricted stock units | 340,542 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 5,626 | — | 5,626 |
| ESPP shares issued | 119,779 | — | — | 770 | — | 770 |
| Net loss | — | — | — | — | (82,852) | (82,852) |
| Balance at March 31, 2024 | 58,524,101 | 5 | 19 | 863,029 | (1,011,537) | (148,503) |
| Vesting of restricted stock units | 74,492 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 6,099 | — | 6,099 |
| Issuance of common stock from exercise of stock options | 2,432 | — | — | 21 | — | 21 |
| Net loss | — | — | — | — | (91,446) | (91,446) |
| Balance at June 30, 2024 | 58,601,025 | $5 | 19 | $869,149 | $(1,102,983) | $(233,829) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.